January 29, 2026 (MLN): Macter International Limited (PSX:MACTER) has successfully launched TirzaTrim (Tirzepatide) in a multidose pre-filled pen (PFP) presentation.

Tirzepatide is a dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist, indicated for the management of Type 2 Diabetes Mellitus, according to the company's statement issued today.

 The medication offers additional benefits in glycemic control and weight reduction, representing a next-generation incretin-based therapy with significant clinical relevance in cardio-metabolic care.

The launch of TirzaTrim Multidose Pre-Filled Pen marks an important milestone in the company's biotechnology portfolio and strengthens Macter's position in advanced injectable drug delivery systems and complex biologics within Pakistan.

The development reflects the company's continued commitment to introducing innovative, patient-centric therapies and expanding access to globally benchmarked treatments in the local market.

The pre-filled pen delivery system is designed to enhance patient convenience and compliance in diabetes management.

Copyright